Related Experiment Video
Updated: Sep 21, 2025
08:01
Generation and Expansion of Primary, Malignant Pleural Mesothelioma Tumor Lines
Published on: April 21, 2022
2.0K
The Evolving Therapeutic Landscape for Malignant Pleural Mesothelioma
Nirosha D Perera1, Aaron S Mansfield2
1Department of Internal Medicine, Mayo Clinic, Rochester, MN, 55905, USA.
Current Oncology Reports
|June 3, 2022
Summary
Malignant pleural mesothelioma has a poor prognosis, but new treatments are emerging. Future therapies combine VEGF inhibition, immune checkpoint inhibitors, and biomarker strategies for improved outcomes.
Area of Science:
- Oncology
- Thoracic Surgery
- Immunotherapy
Background:
- Malignant pleural mesothelioma has a dismal prognosis with limited treatment options.
- Current 5-year survival rates are extremely low, necessitating novel therapeutic approaches.
Purpose of the Study:
- To review the current treatment landscape for malignant pleural mesothelioma.
- To highlight promising future therapeutic directions and emerging treatments.
Main Methods:
- Review of evolving frontline therapies including VEGF inhibition and dual immune checkpoint inhibition.
- Exploration of experimental treatments such as PARP and ALK inhibitors, cell-based therapies, vaccines, and oncolytic viruses.
Main Results:
- Frontline options are evolving with combinations of chemotherapy and VEGF inhibition, and dual immune checkpoint inhibition.
- Experimental treatments show promise, including targeted therapies, immunotherapies, and novel vaccine and viral strategies.
- Biomarker utilization is crucial for predicting treatment response.
Conclusions:
- The therapeutic landscape for malignant pleural mesothelioma is rapidly evolving.
- Multi-modal therapies combining angiogenesis and immune checkpoint inhibitors, alongside biomarker utilization, are key for current and future clinical management.
Keywords:
CAR T-cell therapyGenetic targetsImmunotherapyMalignant pleural mesotheliomaMesothelioma biomarkersVEGF inhibitionMore Related Videos
Related Concept Videos
01:30Pleural Disorders: Types and Brief Description
309
The pleura is a vital part of the respiratory system. It's a double-layered membrane surrounding the lungs and lining the chest cavity. The two layers of the pleura are:
309
02:57Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
01:28Pleural Effusion II: Symptoms and Management
277
Pleural Effusion Overview
A pleural effusion is the abnormal collection of fluid between the parietal and visceral pleura layers of tissue that form the lining of the lungs and chest cavity. It can occur independently or due to surrounding parenchymal diseases, such as infection, malignancy, or inflammatory conditions.
Clinical Manifestations:
A pleural effusion is the abnormal collection of fluid between the parietal and visceral pleura layers of tissue that form the lining of the lungs and chest cavity. It can occur independently or due to surrounding parenchymal diseases, such as infection, malignancy, or inflammatory conditions.
Clinical Manifestations:
277
02:56Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
02:50Combination Therapies and Personalized Medicine
5.1K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K